Literature DB >> 9916059

Vaccination against anthrax with attenuated recombinant strains of Bacillus anthracis that produce protective antigen.

J P Barnard1, A M Friedlander.   

Abstract

The protective efficacy of several live, recombinant anthrax vaccines given in a single-dose regimen was assessed with Hartley guinea pigs. These live vaccines were created by transforming DeltaANR and DeltaSterne, two nonencapsulated, nontoxinogenic strains of Bacillus anthracis, with four different recombinant plasmids that express the anthrax protective antigen (PA) protein to various degrees. This enabled us to assess the effect of the chromosomal background of the strain, as well as the amount of PA produced, on protective efficacy. There were no significant strain-related effects on PA production in vitro, plasmid stability in vivo, survival of the immunizing strain in the host, or protective efficacy of the immunizing infection. The protective efficacy of the live, recombinant anthrax vaccine strains correlated with the anti-PA antibody titers they elicited in vivo and the level of PA they produced in vitro.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 9916059      PMCID： PMC96355     

Source DB:  PubMed          Journal:  Infect Immun        ISSN： 0019-9567            Impact factor:   3.441


  46 in total

1.  Large-scale production of protective antigen of Bacillus anthracis in anaerobic cultures.

Authors:  M PUZISS; L C MANNING; J W LYNCH; I ABELOW; G G WRIGHT
Journal:  Appl Microbiol       Date:  1963-07

2.  Channels formed in phospholipid bilayer membranes by diphtheria, tetanus, botulinum and anthrax toxin.

Authors:  A Finkelstein
Journal:  J Physiol (Paris)       Date:  1990

3.  Field Evaluation of a Human Anthrax Vaccine.

Authors:  P S Brachman; H Gold; S A Plotkin; F R Fekety; M Werrin; N R Ingraham
Journal:  Am J Public Health Nations Health       Date:  1962-04

4.  Protection against anthrax with recombinant virus-expressed protective antigen in experimental animals.

Authors:  L C Iacono-Connors; S L Welkos; B E Ivins; J M Dalrymple
Journal:  Infect Immun       Date:  1991-06       Impact factor: 3.441

5.  The carboxyl-terminal end of protective antigen is required for receptor binding and anthrax toxin activity.

Authors:  Y Singh; K R Klimpel; C P Quinn; V K Chaudhary; S H Leppla
Journal:  J Biol Chem       Date:  1991-08-15       Impact factor: 5.157

Review 6.  Anthrax vaccines: past, present and future.

Authors:  P C Turnbull
Journal:  Vaccine       Date:  1991-08       Impact factor: 3.641

7.  Immunization against anthrax with Bacillus anthracis protective antigen combined with adjuvants.

Authors:  B E Ivins; S L Welkos; S F Little; M H Crumrine; G O Nelson
Journal:  Infect Immun       Date:  1992-02       Impact factor: 3.441

8.  Anthrax toxin protective antigen is activated by a cell surface protease with the sequence specificity and catalytic properties of furin.

Authors:  K R Klimpel; S S Molloy; G Thomas; S H Leppla
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-01       Impact factor: 11.205

9.  Anthrax protective antigen interacts with a specific receptor on the surface of CHO-K1 cells.

Authors:  V Escuyer; R J Collier
Journal:  Infect Immun       Date:  1991-10       Impact factor: 3.441

10.  Improved electroporation and cloning vector system for gram-positive bacteria.

Authors:  G M Dunny; L N Lee; D J LeBlanc
Journal:  Appl Environ Microbiol       Date:  1991-04       Impact factor: 4.792
View more
  19 in total

1.  Search for correlates of protective immunity conferred by anthrax vaccine.

Authors:  S Reuveny; M D White; Y Y Adar; Y Kafri; Z Altboum; Y Gozes; D Kobiler; A Shafferman; B Velan
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

Review 2.  Bacterial infectious disease control by vaccine development.

Authors:  Roy Curtiss
Journal:  J Clin Invest       Date:  2002-10       Impact factor: 14.808

3.  Fully virulent Bacillus anthracis does not require the immunodominant protein BclA for pathogenesis.

Authors:  J Bozue; C K Cote; K L Moody; S L Welkos
Journal:  Infect Immun       Date:  2006-10-30       Impact factor: 3.441

4.  Search for Bacillus anthracis potential vaccine candidates by a functional genomic-serologic screen.

Authors:  Orit Gat; Haim Grosfeld; Naomi Ariel; Itzhak Inbar; Galia Zaide; Yehoshua Broder; Anat Zvi; Theodor Chitlaru; Zeev Altboum; Dana Stein; Sara Cohen; Avigdor Shafferman
Journal:  Infect Immun       Date:  2006-07       Impact factor: 3.441

5.  Attenuated nontoxinogenic and nonencapsulated recombinant Bacillus anthracis spore vaccines protect against anthrax.

Authors:  S Cohen; I Mendelson; Z Altboum; D Kobiler; E Elhanany; T Bino; M Leitner; I Inbar; H Rosenberg; Y Gozes; R Barak; M Fisher; C Kronman; B Velan; A Shafferman
Journal:  Infect Immun       Date:  2000-08       Impact factor: 3.441

6.  Oral spore vaccine based on live attenuated nontoxinogenic Bacillus anthracis expressing recombinant mutant protective antigen.

Authors:  R Aloni-Grinstein; O Gat; Z Altboum; B Velan; S Cohen; A Shafferman
Journal:  Infect Immun       Date:  2005-07       Impact factor: 3.441

7.  The Bacillus anthracis protein MprF is required for synthesis of lysylphosphatidylglycerols and for resistance to cationic antimicrobial peptides.

Authors:  Shalaka Samant; Fong-Fu Hsu; Alexander A Neyfakh; Hyunwoo Lee
Journal:  J Bacteriol       Date:  2008-12-12       Impact factor: 3.490

8.  The anthrax vaccine adsorbed vaccine generates protective antigen (PA)-Specific CD4+ T cells with a phenotype distinct from that of naive PA T cells.

Authors:  William W Kwok; Junbao Yang; Eddie James; John Bui; Laurie Huston; Andrew R Wiesen; Michelle Roti
Journal:  Infect Immun       Date:  2008-08-04       Impact factor: 3.441

9.  Use of a promoter trap system in Bacillus anthracis and Bacillus subtilis for the development of recombinant protective antigen-based vaccines.

Authors:  O Gat; I Inbar; R Aloni-Grinstein; E Zahavy; C Kronman; I Mendelson; S Cohen; B Velan; A Shafferman
Journal:  Infect Immun       Date:  2003-02       Impact factor: 3.441

10.  Molecular subtyping of Bacillus anthracis and the 2001 bioterrorism-associated anthrax outbreak, United States.

Authors:  Alex R Hoffmaster; Collette C Fitzgerald; Efrain Ribot; Leonard W Mayer; Tanja Popovic
Journal:  Emerg Infect Dis       Date:  2002-10       Impact factor: 6.883
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.